Aurora Cannabis (US) (TSE:ACB)
NASDAQ:ACB
Want to see TSE:ACB full AI Analyst Report?
Top Page
Aurora Cannabis
(NASDAQ:ACB)
Select Model
Select Model
Rating:46Neutral
Price Target:
C$4.00
▼(-20.63% Downside)
Action:Reiterated
Date:06/12/26
The score is weighed down primarily by weak financial performance (renewed losses and negative operating/free cash flow) and bearish technical positioning (below major moving averages with weak momentum). The earnings call adds partial support due to strong FY2026 operational metrics and liquidity, but FY2027 guidance indicates a reset year with declining revenue, lower margins, and lower EBITDA. Valuation contributes limited support because the company remains loss-making and has no provided dividend yield.
Positive Factors
International medical market leadership
A majority international revenue mix and double-digit FY2026 top-line growth reduce dependence on the weak Canadian consumer market. Durable medical focus in Europe, Australia and NZ and EU‑GMP capacity give structural access to higher‑margin, regulated markets and support steadier long‑term demand.
Negative Factors
Canadian reimbursed‑rate cut
A regulatory-driven ~30% cut to reimbursed pricing materially and persistently reduces Canadian medical revenue and margins. Given Canada’s historic importance, this structural policy shift forces portfolio exits and a strategic reset that will depress consolidated revenue and EBITDA through FY2027 and beyond if unchanged.
Read all positive and negative factors
Positive Factors
Negative Factors
International medical market leadership
A majority international revenue mix and double-digit FY2026 top-line growth reduce dependence on the weak Canadian consumer market. Durable medical focus in Europe, Australia and NZ and EU‑GMP capacity give structural access to higher‑margin, regulated markets and support steadier long‑term demand.
Read all positive factors
Aurora Cannabis (ACB) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$253.96M
Dividend YieldN/A
Average Volume (3M)405.01K
Price to Earnings (P/E)―
Beta (1Y)1.68
Revenue Growth-6.61%
EPS Growth-3770.67%
CountryCA
Employees1,073
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-2.14
Shares Outstanding61,942,146
10 Day Avg. Volume561,704
30 Day Avg. Volume405,013
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.51
Price to Sales (P/S)0.81
P/FCF Ratio-7.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$6.50Price Target Upside28.97% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.13
Revenue Forecast (FY)C$289.50M
Aurora Cannabis Business Overview & Revenue Model
Company Description
Aurora Cannabis Inc. is a Canada-based firm specializing in the cultivation, processing, and global distribution of cannabis and its various derivative products. The company's operations encompass a broad spectrum of the cannabis industry, from fa...
How the Company Makes Money
Aurora Cannabis makes money primarily by selling cannabis products through two main channels: (1) medical cannabis sales and (2) consumer (adult-use) cannabis sales. In its medical business, Aurora generates revenue by supplying cannabis products ...
Aurora Cannabis Earnings Call Summary
Earnings Call Date:Jun 11, 2026
(Q4-2026)
| % Change Since: |
Next Earnings Date:Aug 12, 2026
Earnings Call Sentiment Positive
The call conveyed a predominantly positive operational and financial performance for FY2026 — double-digit revenue growth, strong adjusted gross margins (64%), 32% growth in adjusted EBITDA to CAD 54M, solid international momentum, accretive M&A (Safari) and a strong cash position (CAD 165M, no debt). However, the company signaled a near-term reset driven by a material (~30%) reduction in Canadian reimbursed pricing effective April 1, which will pressure FY2027 revenue, margins (guidance to mid-to-high 50s) and annual adjusted EBITDA despite targeted investments in higher-margin international markets. Overall, strong historic execution and balance sheet strength outweigh the headwinds, but FY2027 is expected to be transitional as management reallocates resources and expands EU GMP capacity.Positive Updates
Record FY2026 Revenue and International Mix
Net revenue rose 11% year-over-year to CAD 321 million in FY2026, exceeding the top end of guidance by CAD 8 million; ~55% of net revenue was generated outside of Canada, reflecting strong international diversification.
Negative Updates
Canadian Reimbursement Cut Driving FY2027 Headwinds
Regulatory change effective April 1 (VAC change) represents roughly a 30% reduction in the reimbursed rate for impacted products, which the company expects to materially reduce Canadian medical topline and margins in FY2027 and drive total net revenue to be more in line with FY2025.
Read all updates
Q4-2026 Updates
Positive
Negative
Record FY2026 Revenue and International Mix
Net revenue rose 11% year-over-year to CAD 321 million in FY2026, exceeding the top end of guidance by CAD 8 million; ~55% of net revenue was generated outside of Canada, reflecting strong international diversification.
Read all positive updates
Company Guidance
For fiscal 2027 Aurora guided that total net revenue is expected to decline (to be more in line with its fiscal‑2025 cannabis net‑revenue level) as the company completes its exit from lower‑margin Canadian consumer and plant‑propagation businesses by end‑September and absorbs an approximate 30% reduction in the reimbursed rate effective April 1; adjusted gross margins are expected in the mid‑to‑high 50s (down from FY2026’s 64% and Q4’s 60%, with medical margin at 66%); adjusted SG&A is expected to be broadly in line with the prior fiscal year (Q4 adj. SG&A CAD 40.3M vs CAD 35.4M prior year); adjusted EBITDA is expected to be lower on an annual basis and more variable quarter‑to‑quarter versus FY2026’s CAD 54M (Q4 adj. EBITDA CAD 9.2M); management will continue to invest in international growth and EU‑GMP capacity (Safari acquisition ~CAD 26.5M; Safari facility 59,000 sq ft; company noted ~40% increase in EU‑GMP capacity over five years and Leuna expansion to double annual flower output in H1 FY2027), and enters the year with CAD 165M of cash and equivalents, no debt, a 25‑month shelf prospectus and an ATM program to issue up to US$100M of common shares.Aurora Cannabis Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
66
Positive
Cash Flow
38
Negative
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 320.59M | 343.29M | 270.28M | 233.29M | 221.34M |
| Gross Profit | 16.70M | 187.61M | 131.46M | -64.36M | 21.23M |
| EBITDA | -162.79M | 51.35M | -12.34M | -210.74M | -1.55B |
| Net Income | -121.76M | 1.59M | -69.33M | -265.33M | -1.72B |
Balance Sheet | |||||
| Total Assets | 601.09M | 852.67M | 838.67M | 926.32M | 1.08B |
| Cash, Cash Equivalents and Short-Term Investments | 164.69M | 138.47M | 117.47M | 300.84M | 439.14M |
| Total Debt | 23.86M | 104.58M | 104.79M | 227.52M | 269.49M |
| Total Liabilities | 89.25M | 244.07M | 236.80M | 409.19M | 422.00M |
| Stockholders Equity | 511.83M | 567.17M | 559.77M | 486.08M | 661.84M |
Cash Flow | |||||
| Free Cash Flow | -36.06M | -2.85M | -85.46M | -127.95M | -142.48M |
| Operating Cash Flow | -13.51M | 16.00M | -68.51M | -115.82M | -110.27M |
| Investing Cash Flow | -73.43M | -14.33M | -5.49M | -27.29M | -36.17M |
| Financing Cash Flow | 9.76M | -116.00K | -47.92M | -56.48M | 147.78M |
Aurora Cannabis Technical Analysis
Negative
5.04
Price Trends
4.69
Negative
4.78
Negative
5.73
Negative
Market Momentum
-0.17
Positive
34.92
Neutral
35.92
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:ACB, the sentiment is Negative. The current price of 5.04 is above the 20-day moving average (MA) of 4.57, above the 50-day MA of 4.69, and below the 200-day MA of 5.73, indicating a bearish trend. The MACD of -0.17 indicates Positive momentum. The RSI at 34.92 is Neutral, neither overbought nor oversold. The STOCH value of 35.92 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:ACB.
Aurora Cannabis Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | C$2.32B | 14.51 | 6.59% | ― | 4.14% | 146.77% | |
67 Neutral | C$1.40B | -1,203.85 | -0.19% | ― | 27.16% | -103.47% | |
56 Neutral | C$3.63B | -25.08 | -12.61% | ― | -2.25% | 55.22% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | C$618.04M | -1.62 | -35.48% | ― | 5.80% | 85.58% | |
46 Neutral | C$253.96M | -1.82 | -14.05% | ― | -6.61% | -3770.67% |
* Healthcare Sector Average
TSE:ACB
Aurora Cannabis
4.10
-1.27
-23.65%
TSE:WEED
Canopy Growth
1.39
-0.26
-15.76%
TSE:CRON
Cronos Group
3.75
1.20
47.06%
TSE:CURA
Curaleaf Holdings
13.74
10.53
328.04%
TSE:GTII
Green Thumb Industries
10.60
3.99
60.36%
Aurora Cannabis Corporate Events
Business Operations and Strategy
Aurora Cannabis Earns Repeat Honour for Executive Gender Diversity
Positive
Mar 30, 2026
Aurora Cannabis has been named to The Globe and Mail’s 2026 Women Lead Here list for the second consecutive year, recognizing the company among 85 Canadian public issuers with 50% female representation at the executive level. The acknowledgm...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.